An mRNA-based personalized cancer vaccine combined with immune checkpoint therapy shows substantial tumor control in a Phase 2 clinical trial
Tag: Personalized
Personalized Cancer Vaccine Intismeran Autogene Shows Promising Phase 2 Results at ASCO 2026
Phase 2 trial presented at ASCO annual conference shows that the personalized mRNA cancer vaccine intismeran autogene improves outcomes in solid tumors